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Purpose: The present study reports for the first time a large-scale proteomic screening of the
occurrence, subcellular localization and relative quantification of the S100A7 protein among a
group of 100 patients, clinically grouped for the diagnosis of infiltrating ductal carcinoma (IDC).
Experimental design: To this purpose, themethods of differential proteomics,Western blotting,
and immunohistochemistry were used.
Results: The identity of two isoforms of the protein was assessed bymass spectrometry and im-
munologically confirmed.Moreover, we proved by immunocytochemical applications the exclu-
sive localization of the protein within the neoplastic cells. The correlation of S100A7 expression
levels with the collective profile of cancer patients’ proteomics predicted functional interactions,
distinct for the two isoforms. The S100A7b isoform was significantly correlated with specific
protein clusters (calcium binding, signaling and cell motion, heat shock and folding) and in-
tercrossing pathways (antioxidant, metabolic and apoptotic pathways), while the more acidic
isoform was correlated with a narrow number of proteins mainly unrelated to the b isoform.
Conclusions and clinical relevance: This study is the first proteomic-based report on S100A7
in a large series of IDC patients. The correlation with in silico data may significantly contribute
the knowledge of possible pathways for S100A7, providing novel insights into the mechanism
of action of this protein. We suggest that each S100A7 isoform is involved in critical phases of
the breast cancer growth and progression, probably through interaction with different partner
proteins.
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1 Introduction
S100A7 protein, also named Psoriasin, is a member of the
EF-hand superfamily of S100-calcium-binding proteins, so
called because of their solubility in a saturated solution of
ammonium sulphate. The first member of this family was
identified in the nervous system in 1965 [1].
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Presently, the knownmembers of the S100 protein family
in humans are at least 25, differentially expressed in tissues
and cells, suggesting the existence of diversified functions of
the family members according to given phenotypes [2]. Most
of them form homo- or heterodimers and some oligomers,
in the presence or absence of calcium [3]. The repertory of
S100 protein functions covers several biological processes,
through a broad range of intracellular and extracellular ac-
tivities [4, 5]. Intracellular functions include control and/or
regulation of calcium homeostasis, protein phosphorylation,
cell cycle and growth control, cell differentiation, cytoskele-
ton reorganization and motility, and transcriptional activi-
ties [5, 6]. Extracellularly, they act in a cytokine like manner
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through a transmembrane receptor of the immunoglobulin
superfamily named RAGE (receptor for advanced glycation
endproducts) [7].
In consideration of the critical roles played by S100 pro-
teins in such large spectrum of biological activities, it is not
surprising that improper expression of S100 members is cor-
related with many pathologies and especially with cancer. A
number of S100 proteins have been shown to interact with
oncogenes and various proteins involved in cancer progres-
sion, including p53, cytoskeletal proteins, matrix metallopro-
teinases (MMPs), and others, either in calcium-dependent or
calcium-independent ways [8]. Moreover, there are also sev-
eral evidences that overexpression of S100 proteins occurs in
cancer, for which reason it is proposed their clinical applica-
tion for the diagnosis and staging of human tumors, as well
as for prediction of prognosis [9, 10].
In a previous study, we have described a large-scale pro-
teomic investigation performed on breast cancer patients for
the screening of multiple forms of S100 proteins [11].
The results have shown that some S100 protein members
were ubiquitously expressed in almost all patients, while oth-
ers appeared more sporadic among the same group, without
apparent correlation with the clinical parameters. Most of
the detected S100 members appeared reciprocally correlated.
Among the sporadic forms of S100 proteins, the S100A7 was
one of the prominent, also for the high level of relative con-
centration reached in many cases.
S100A7 was originally identified as a protein overex-
pressed in psoriatic keratinocytes [12], since then it has been
found overexpressed in several carcinomas, including skin
[13], oral squamous cell carcinoma [14], esophagus [15], blad-
der [16], lung [17], as well as adenocarcinomas of the stomach
[18] and the breast [19–23].
Psoriasin was found to be secreted but also present in
the cytoplasm and the nucleus of cells expressing it. Secreted
S100A7 may exert a chemotactic potential [24] and more re-
cently, it has been implicated in inflammation with an an-
tibacterial action [25]. Meanwhile, S100A7 is also believed
to be associated with several intracellular proteins such as
RanBPM [26], epidermal fatty acid binding protein [27], and
Jab-1 [28].
However, the knowledge on the involvement S100A7 in
cancer is based mostly on in vitro models and this is a lim-
itation due to the difficulty of conducting basic research on
human biopsies. In the present study, our aim was to add
information to the in vivo expression of the S100A7 by: (i)
determining the frequency of its occurrence in a large series
of ductal infiltrating surgical tissues; (ii) to detect its local-
ization within the tumor tissues; (iii) to ascertain its possi-
ble relationships to protein clusters generated by differential
proteomic profiling on the patient’s maps. With this pur-
pose, the methods of differential proteomics, MALDI-TOF
spectrometry, Western blotting, and immunohistochemistry
(IHC) were used.
Our results confirmed the sporadic occurrence of S100A7
among patients and showed that, when present, the protein
is primarily expressed in breast cancer cells and not in the
unaffected glandular structures or in the mesenchymal cells.
Moreover, the existence of two isoforms of S100A7, arbitrarily
named a and b, with different levels of silver-stained intensity
among patients, was noticed.
Statistical applications, to explore possible correlations of
S100A7a and b expression levels with patient proteomics,
showed a diversified pattern for the two isoforms.
The S100A7b isoform was significantly correlated with a
broad range of proteins involved in cytoplasmic activities (cal-
cium binding, signaling and cell motion, heat shock and fold-
ing) and crossing pathways (antioxidant, metabolism, regula-
tion of apoptosis). On the contrary, S100A7a was correlated
with a limited number of apparently unrelated proteins, six
of which also unrelated to the b isoform and with key roles in
cancer progression.
2 Materials and Methods
2.1 Clinical specimens
Aliquots of breast cancer and its adjacent nontumoral tissues
were obtained during surgical intervention between 2003 and
2007 in the Breast Unit of the LaMaddalenaHospital and im-
mediately frozen at −80C until used. Research was carried
out in compliance with the Helsinki Declaration with the
patients’ written consent and with the approval of the Insti-
tutional Review Board (N515/2008) from the La Maddalena
Hospital. The patients of this study did not receive any cyto-
toxic/endocrine treatment prior to surgery. Diagnosis of duc-
tal breast cancer (G2/G3) was confirmed histopathologically.
2.2 Sample preparations
Sample preparation and analysis was carried out essentially
as described in [11]. The frozen breast tissue samples were
washed several times with PBS and homogenized in RIPA
buffer (50 mM Tris pH 7.5, 0.1% Nonidet P-40, 0.1% deoxy-
cholate, 150 mM NaCl, 4 mM EDTA), containing a mixture
of protease inhibitors (0.01% aprotinin, 10 mM sodium pyro-
phosphate, 2 mM sodium orthovanadate, 1 mM PMSF). The
extraction was carried out overnight at 4C with the same
buffer. The total cellular lysate was centrifuged to remove
tissue debris, and the resulting supernatant dialysed against
ultrapure distilled water, lyophilized and stored at −80C un-
til use. The total protein concentration was determined by the
Bradford method using bovine serum albumin as a standard.
2.3 2D-IPG
The proteins extracted from breast cancer tissues and normal
adjacent tissues were solubilized in a buffer containing 4%
CHAPS, 40 mM Tris, 65 mM DTE in 8 M urea. Aliquots of
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45 g (analytical gels) or 1.5 mg (preparative gels) of total
proteins were separately mixed with 350 L of rehydration
solution containing 8 M urea, 2% CHAPS, 10 mM DTE, and
0.5% carrier anpholytes (Resolyte 3.5–10), and applied for
IEF using commercial sigmoidal IPG strips, 18-cm long with
pH range 3.0–10. The second dimension was carried out on
9–16% linear gradient polyacrylamide gels (SDS-PAGE), and
the separated proteins were visualized by ammoniacal silver
staining.
2.4 Image acquisition and data analysis
Silver stained gels were digitized using a computing densito-
meter and analyzed with Image Master software (Amersham
Biosciences, Uppsala, Sweden).
Quantitative expression levels were calculated as the vol-
ume of the spots (i.e., integration of optical density over the
spot area). In order to correct for differences in gel staining,
spot volumes relative to the sum of the volume of all spots
on each gel (%Vol) were calculated by the software. Measure-
ments of relative expression levels of individual protein spots
were normalized in each map for actin content (N%V) [29].
For statistical analyses Ms Excel and Graph Pad Prism 4
software were used. Correlation of S100A7 protein with the
collective profile of cancer patients proteomicswas performed
using the Pearson correlation test. p <0.05* was considered
significant, p <0.01** was considered highly significant, p <
0.001*** was considered very highly significant.
2.5 Protein identification
N-Terminal microsequencing was performed by automated
Edman degradation in a protein sequencer (Procise, 419 Ap-
plied Biosystems, Monza, Milano, Italy), as previously de-
scribed [30]. Mass spectrometric sequencing was performed
by Voyager DE-PRO (Applied Biosystems) mass spectrom-
eter as described [31]. Briefly, proteins were digested us-
ing sequencing-grade trypsin (20 g/vial). The tryptic pep-
tide extracts were dried and redissolved in 10 L of 0.1%
TFA. Thematrix, CHCA,was purchased fromSigma-Aldrich,
St. Louis, MO, USA. A saturated solution of CHCA (1 L)
at 2 mg/200 L in CH3CN/H2O (50:50 (v/v)) containing
0.1% TFA was mixed with 1 L of peptide solution on the
MALDI plate and left to dry. MALDI-TOF mass spectra were
recorded in the 500–5000 Da mass range, using a minimum
of 100 shots of laser per spectrum. Delayed extraction source
and reflector equipment allowed sufficient resolution to con-
sider MH+ of monoisotopic peptide masses. Internal cali-
bration was done using trypsin autolysis fragments at m/z
842.5100, 1045.5642, and 2211.1046 Da. Peptide mass fin-
gerprinting was compared to the theoretical masses from
the Swiss-Prot or NCBI sequence databases using Mascot
http://www.matrixscience.com/. Typical search parameters
were as follows: 50 ppm of mass tolerance, carbamidomethy-
lation of cysteine residues, onemissed enzymatic cleavage for
trypsin, a minimum of four peptide mass hits was required
for a match, and methionine residues could be considered in
oxidized form.
2.6 Western blotting
For immune detection, the 1D or 2D gels were electro-
transferred onto nitrocellulose membrane (HyBond ECL,
Amersham Biosciences) and stained with Ponceau S (Sigma
Aldrich). Themembranes were then probed withmonoclonal
anti-S100A7 (Santa Cruz, Heidelberg, Germany; 1:1000). Fol-
lowing incubation with the peroxidase-linked mouse anti-
body, the reaction was revealed by the ECL detection system,
using high-performance films (Hyperfilm ECL, Amersham
Biosciences).
2.7 Immunohistochemistry
Sections of 3-m thick of formalin-fixed, paraffin-embedded
surgical breast specimens were deparaffinized in xylene and
rehydrated with distilled water. After antigen retrieval in cit-
rate buffer, staining was performed using the BenchMark au-
tomated staining system (Ventana Medical System, Tucson,
AZ, USA) with monoclonal S100A7 antibody (Santa Cruz;
1:500). Signal was detected with EnVision R© Plus System–
HRP (Dako UK, Ely, UK), and visualized with diaminobenzi-
dine. Slideswere then counterstained inMayer’s hematoxylin
for 10 s, dehydrated in graded alcohol, andmounted. Negative
controls, where primary antibodywas omitted, were included.
2.8 Bioinformatics
DAVID (the databases for annotation, visualization, and in-
tegrated discovery) was used for functional analysis. DAVID
bioinformatics (http://david.abcc.ncifcrf.gov/) were released
in 2003 and extract biological features associated with
gene/protein lists. The current version of DAVID not only
keeps a gene-GO term enrichment analysis algorithm, but
increase over 40 annotation categories with extended annota-
tion content coverage, classifying the gene list into function-
ally related gene groups.
3 Results
3.1 Proteomics and immunological validation
of S100A7
Figure 1 shows the miniatures of 100 proteomic maps of
breast cancer tissue extracts used in the current research,
each displaying an individual protein signature, for inten-
sity and number of detectable protein spots, under the same
protein loading. The number on each map corresponds to
a selected patient. A reference synthetic gel was thereby
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Figure 1. Miniatures of 100 proteomic maps of breast cancer tissue extracts used in the current research. The number on the right corner
of each map corresponds to a selected patient.
generated after spot pairs have been determined for each of
the 100 maps’ collection, according to the Image Master soft-
ware directions. Figure 2 shows the synthetic gel image, as a
reference infiltrating ductal carcinoma (IDC) map, in which
only identified proteins are imported and labeled according to
the Swiss-prot accession number. The two spots with joined
AC number P31151 correspond to the two isoelectric forms
of the S100A7 protein. The more prominent displays MW of
11 042 Da and pI of 6.0, which represent the closest expected
values of the protein (11 470–6.27), while the second spot,
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Figure 2. Synthetic gel image, used as a
reference IDC map, in which only iden-
tified proteins are imported and labeled
according to the Swiss-prot accession
number. The two spots with joined AC
number P31151 (marked in bold) corre-
spond to the two isoelectric forms of the
S100A7 protein.
usually less intense than the former, is focused in a more
acidic pI (5.35).
To validate these results, we performed parallel 2D-IPG
separations followed, respectively, by silver staining and
Western blot assays, using the monoclonal anti-S100A7 an-
tibody. The Fig. 3A and B show two gel windows containing
the two S100A7 isoforms stained with silver (A), and revealed
by western, respectively. An optimal correspondence of the
protein-spot intensity levels with both different revelation sys-
tems was observed.
3.2 Spectrometric analysis of the two
S100A7 isoforms
The Fig. 4 reports the list of the most prominent m/z values
identified by the MALDI-TOF spectrometry and sequence
coverage of the S100A7a and b, respectively. As shown, the
peptide mass fingerprinting of the isoform b covers about
95% of the theoretical masses from the Swiss-Prot sequence
database. On the contrary, coverage of the isoform a is of
about 60% of the protein. The unmatching portion of the
S100A7a contains part of a putative EF-hand domain, part
of a putative calcium-binding domain and two zinc-binding
residues.
Figure 3. Panel showing two gel windows from 2D-IPG com-
prising an area covering a pI/kDa range of 5.5–6.5/12–9 kDa, in
which the S100A7 protein spots are focused. The protein spots
are stained with silver (A), and revealed by Western blot with
anti-S100A7 antibody (B), respectively.
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Figure 4. Listing of the most prominentm/z values identified by the MALDI-TOF spectrometry and sequence coverage of the two S100A7a
and b, respectively.
3.3 Differential S100A7 occurrence
The differential expression of the S100A7 forms among the
100 patients was recorded in the matched proteomic maps.
The qualitative evaluation revealed the presence of protein
spots corresponding to the S100A7a and b in 51 and 63 pa-
tients, while they were undetectable in 49 and 37 patients,
respectively.
The relative abundance of each isoform was then calcu-
lated in the positive cases, following the Image Master algo-
rithms and spot normalization for actin content. According to
this methods, we generated three different expression levels,
namely low (N%V 0.01–0.09), medium (N%V 0.1–0.19), and
high (N%V ≥0.2). A more detailed description of the S100A7
expression levels is represented in the graph in Fig. 5. As
it is possible to observe, while the isoform a is undetectable
in 49% of patients, the isoform b is undetectable in 37% of
patients. Each isoform is expressed at low level in 42% of
patients and at medium expression levels, respectively, in 9%
and 10%. Only isoform b is expressed at high levels in 11%
of patients.
3.4 Immunolocalization of S100A7
In consideration of the equivalent immunological reactiv-
ity of the two isoforms to the full-length S100A7 antibody
(Santa Cruz), we then investigated the tissue localization of
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Figure 5. Diagrams reporting the level distributions of the
S100A7 among patients. The protein spot expression level was
calculated in each map as the %Vol normalized for actin content.
The range of values are expressed on an arbitrary scale, from
0.01 to >0.2, and indicated as: low (0.01–0.09), medium (0.1–0.19)
and high (>0.2) expression level.
Figure 6. Panel of histoimmunochemical micrographs of three
representative cases of IDC, where the reaction to anti-S100A7
antibody was scored as negative (A/B), moderate (C/D), or strong
(E/F). In all cases, the cellular localization is restricted to the neo-
plastic cells population and absent in the stromal components. In
figures, (D–F) is possible to observe both cytoplasmic and nuclear
localization of the staining. (A–C–E): original magnification ×100;
(B–D–F): original magnification ×200.
S100A7 on paraffin embedded sections, chosen randomly
among tumor explants of our collection. Figure 6 presents
a panel of histoimmunochemical micrographs of three rep-
resentative cases, where the reaction was scored as negative
(A/B), moderate (C/D), or strong (E/F). The cellular localiza-
tion, as it can be observed at low and higher magnification,
is clearly restricted to the neoplastic cells population, while
the nonaffected ducts and the stromal cells, including en-
Figure 7. Monodimensional Western blot of S100A7 expression
from prototypes of matched breast cancer tissues (BCT) and non-
tumoral adjacent tissues (NAT).
dothelium, were entirely negative. The sections in figure E/F
reveals that the expression of high levels of S100A7 is corre-
lated with an extensive number of neoplastic cells with cyto-
plasmic and nuclear positivity. Validation of IHC results was
performed in tissue extracts. A group of eight tumor samples
selected among the ones showing proteomic positivity for
S100A7 were compared with their nontumoral paired surgi-
cal tissues. Figure 7 shows the Western blot assay performed
on monodimensional gels, revealing the unique expression,
even at different levels, of the protein in the tumor tissue
extracts and its absence in the adjacent nontumoral tissues.
3.5 Proteomic correlations of S100A7 and functional
classification
Correlation analyses of the relative expression levels of
S100A7 isoforms and the protein complement detected in the
100 patients’mapswere performed by the graph-pad software
using Pearson correlation. A p value less than 0.05 was con-
sidered significant, a p value less than 0.01 was considered
highly significant and a p value less than 0.001 very highly
significant.
Among the 206 protein spots identified in our proteomic
maps, 43 (21% of the total proteins) were significantly corre-
lated with S100A7. Specifically, ten of them were correlated
with the more acidic S100A7 form, 37 with the more ba-
sic one, while only four (ANXA2 b, ANXA5, one isoform of
ENOA, and PRDX6) were correlated with both S100A7 iso-
forms. Table 1 shows the list corresponding to the S100A7-
associated proteins.
The functional classification performed by bioinformatic
databases resolved the catalogue of S100A7-associated pro-
teins into different clusters trough that S100A7 isoforms
may operate with direct or indirect interactions. In partic-
ular, the S100A7b was found related at high score to proteins
with prominent cytoplasmic activities and crossing pathways,
such as calcium binding (CALM, CALR, S100A2, S100A4,
S100A6b, S100A8, S100A11, ANXA2b, ANXA5), signaling
and cell motion (GDIS, TPM4, VINC), heat shock and fold-
ing (HSP74, PPIA), antioxidant pathways (PRDX1, PRDX6,
SODM, GSTP1) metabolic pathways (ACON, ALDR, LDHA,
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Clinical Relevance
In this study, we describe a large-scale proteomic in-
vestigation performed on 100 breast cancer patients
for the screening of multiple forms of S100A7 pro-
tein. Our present contribution concerns the incidence
of S100A7 protein in breast cancer patients and its
correlation with the collective profile of cancer pa-
tients’ proteomics.
We believe that this experimental effort may re-
spond to a present-day challenge of the oncologic
research and that may offer a significant contribu-
tion to the knowledge and clinical applications of the
S100 protein family.
Table 1. S100A7-associated proteins
S100A7a S100A7b
ACON – p < 0.001***
ALDR a – p < 0.01**
ALDR b – p < 0.05*
AN32A – p < 0.05*
ANXA2 b p < 0.05* p < 0.05*
ANXA5 p < 0.05* p < 0.05*
CALM − p < 0.01**
CALR − p < 0.05*
CATD b – p < 0.05*
EF1B – p < 0.05*
ENOA a – p < 0.01**
ENOA d p < 0.05* p < 0.01**
G3P b – p<0.05*
GDIR p < 0.001*** –
GDIS – p < 0.05*
GSTP1 – p < 0.01**
HSP60 b p < 0.05* –
HSP74 – p < 0.05*
LDHA – p < 0.05*
LDHB – p < 0.01**
LEG1 b – p < 0.05*
NDKB – p < 0.01**
NTF2 – p < 0.01**
PHB – p < 0.05*
PPIA c p < 0.01** –
PPIA e – p < 0.05*
PRDX1 c – p < 0.05*
PRDX6 p < 0.05* p < 0.05*
PSA5 – p < 0.01**
RABP2 p < 0.01** –
S100A2 – p < 0.05*
S100A4 – p < 0.001***
S100A6 b – p < 0.05*
S100A8 – p < 0.001***
S100A11 – p < 0.01**
SODM b – p < 0.001***
TAGL2 sf p < 0.001*** –
TPM4 b – p < 0.01**
TYPH – p < 0.05*
UBIQ a p < 0.05* –
UBIQ b – p < 0.05*
VINC a – p < 0.05*
VINC b – p < 0.05*
* significant; ** highly significant *** very highly significant.
LDHB, ENOA, G3Pb, TYPH) and regulation of apoptosis
(AN32A,ANXA2b, ANXA5,CATD,UBIQ,EF1B, LEG1,PHB,
NDKB, NTF2, PSA5).
On the contrary, the S100A7a was correlated with a re-
stricted number of apparently unrelated proteins, six of which
also unrelated to the b isoform (GDIR, HSP60, an isoform of
PPIA, RABP2, TAGL2 sf, an isoform of UBIQ).
4 Discussion
We report here a large-scale proteomic screening of S100A7
calcium-binding protein among a group of 100 patients op-
erated for ductal infiltrating carcinoma of the breast.
The identity of the two isoforms was assessed by mass
spectrometry and immunologically confirmed. The two iso-
electric forms, arbitrarily named S100A7a and S100A7b, dis-
played similar MW and distinct pI; the S100A7b focused in a
slightly more basic pI and appeared more intense than to the
S100A7a, usually expressed at low intensity levels. The mass
spectrometry analysis showed a sequence coverage with the
theoretical masses from the Swiss-Prot sequence database of
about 95% for isoform b, and about 60% for the isoform a,
in which one of three of the sequence to the carboxy ter-
minus was uncovered by the mass fingerprinting search.
Since this portion contains part of functional domains of the
S100A7, namely a putative EF-hand domain, part of a putative
calcium-binding domain and two zinc-binding residues, it is
reasonable to believe that the two isoforms may exert diversi-
fied functions in the cell. We think that this is an important
contribution to the knowledge of S100A7 isoforms in gen-
eral, but also for their sporadic occurrence in breast cancer:
an open intriguing question that deserves further investiga-
tion.
Retrospective immunohistological search on paraffin em-
bedded tumor explants, selected among S100A7 proteomic-
positive cases, showed the exclusive localization of the
S100A7 immune-reaction within the neoplastic cells, while
it was undetectable in the healthy glandular structure and
in the surrounding stroma. The absence of clear immune-
reaction in the nonaffected tissue around the tumor was also
confirmed by western blot assays on tissue extracts from the
paired nontumoral tissues of the selected cases.
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Several authors have also reported specific expression
of S100A7, at both mRNA and protein levels in neoplas-
tic tissues, and its absence in paired noncancerous tissues
[17, 32], while according to other authors S100A7 is among
the most highly expressed genes in preinvasive ductal car-
cinoma in situ [33], and downregulated with progression to
invasive carcinoma [19,21]. On the other hand, the persistent
overexpression of S100A7 in invasive breast carcinomas is
considered a prognostic sign of poor clinical outcome, es-
pecially in estrogen receptor-negative invasive ductal carci-
nomas [22, 23]. So far, several putative functions have been
proposed to explain the involvement of S100A7 protein in
breast tumor progression [34]. For instance, some authors
have suggested that Psoriasin may support cell invasion, an-
giogenesis and enhance selection for cells, promoting the
upregulation and downregulation of MMP-13 and vascular
endothelial growth factor, respectively [35–37]. However, it
has not been so far established whether S100A7 contributes
to breast cancer growth or metastasis. Our data are the first
contribution to the possible role of S100A7 isoforms within
a proteome-functional clusterization of S100A7-associated
proteins.
A major point of interest is the existence of two distinct
isoforms of the S100A7, which correlate at different extent
with protein clusters, expressed by the patient’s proteomics.
The apparentlymajor form, the b isoform, is significantly cor-
related with at least 33 different proteins involved in critical
cellular activities and metabolic pathways. On the contrary,
the isoform a, which appears as minoritaire for level of abun-
dance and occurrence within patients, is related to a relative
small number of proteins apparently unrelated to each oth-
ers, but with key roles in cancer progression, such as GDIR,
TAGL2, and RABP2 [38–40].
As a result of this knowledge, we suggest that these impor-
tant cellular processes/pathways may be the central mediator
in several of the biological circuits through which S100A7
promote tumor progression in breast cancer cells.
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